Fisetin Fights Atherosclerosis by Rewiring Cholesterol Metabolism
A flavonoid found in strawberries activates a key nuclear receptor to slash cholesterol and reverse arterial plaque in mice.
Summary
Fisetin, a natural flavonoid found in fruits and vegetables, significantly reduced atherosclerotic plaque formation in high-fat-diet-fed ApoE-knockout mice. The compound works by activating FXR, a nuclear receptor that governs cholesterol and bile acid metabolism in the liver. Fisetin lowered total cholesterol, LDL, and triglycerides while reducing oxidative stress and inflammation. It also boosted transintestinal cholesterol excretion (TICE), a pathway where the gut directly eliminates cholesterol from the body. Key proteins involved in cholesterol synthesis (HMGCR, PCSK9) were downregulated, while those promoting cholesterol clearance (LDLR, ABCG5, ABCG8) were upregulated. These dual hepatic and intestinal mechanisms make fisetin a compelling candidate for cardiovascular disease prevention.
Detailed Summary
Atherosclerosis remains a leading driver of cardiovascular mortality, and dysregulated cholesterol homeostasis is its primary fuel. Finding dietary compounds that can safely restore cholesterol balance is a major goal in preventive medicine and longevity research.
This study examined fisetin, a flavonoid abundant in strawberries, apples, and onions, in ApoE-deficient mice fed a high-fat diet — a well-established model of atherosclerosis. Researchers used biochemical assays, histopathology, untargeted lipidomics, and RNA sequencing to map fisetin's mechanisms comprehensively.
Fisetin treatment markedly reduced lipid deposition in the aortic root and liver, and lowered serum total cholesterol, LDL cholesterol, and triglycerides. Hepatic lipidomics showed broad reductions in pro-atherogenic lipid species including cholesteryl esters, phosphatidylcholines, and triglycerides, alongside increased cardioprotective phosphatidylserine. RNA sequencing pointed to FXR (encoded by Nr1h4) and cytochrome P450 enzymes as central targets, confirmed by molecular docking analysis.
In the liver, fisetin modulated a suite of cholesterol-regulating proteins: it suppressed HMGCR and PCSK9 (reducing synthesis and promoting LDL receptor recycling) while enhancing bile acid synthesis enzymes CYP7A1, CYP27A1, and CYP8B1, and boosting ABCG5/G8 transporters that pump cholesterol into bile. In the intestine, fisetin stimulated the TICE pathway by upregulating FXR, ABCG5, ABCG8, and LDLR while downregulating NPC1L1, increasing fecal neutral sterol excretion.
These findings position fisetin as a dual-action cholesterol-lowering agent operating through both hepatic bile acid conversion and direct intestinal cholesterol elimination. While results are preclinical, the multi-pathway mechanism and dietary availability of fisetin make it a strong candidate for human trials targeting cardiovascular and metabolic longevity.
Key Findings
- Fisetin reduced aortic root lipid deposition and lowered serum LDL, total cholesterol, and triglycerides in ApoE-/- mice.
- FXR activation by fisetin upregulated bile acid synthesis enzymes CYP7A1 and CYP27A1, enhancing hepatic cholesterol clearance.
- Fisetin suppressed PCSK9 and HMGCR while increasing LDLR expression, promoting LDL receptor-mediated cholesterol uptake.
- Intestinal TICE pathway was stimulated via increased ABCG5/G8 and decreased NPC1L1, boosting fecal cholesterol excretion.
- Hepatic lipidomics confirmed broad reductions in pro-atherogenic lipid species including cholesteryl esters and lysophosphatidylcholines.
Methodology
ApoE-/- mice on a high-fat diet were treated with fisetin; outcomes were assessed via biochemical panels, histopathology, untargeted hepatic lipidomics, and liver RNA sequencing. Molecular docking was used to evaluate fisetin-FXR binding interactions. The study is preclinical and limited to a mouse model.
Study Limitations
Results are derived entirely from an ApoE-/- mouse model, which may not fully replicate human atherosclerosis biology. Optimal dosing, bioavailability, and long-term safety of fisetin in humans remain unestablished. The study lacks in vitro mechanistic validation or human data to confirm FXR as a direct functional target.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.